The Development of Mongolian Medicine Seabuckthorn Syrup Based on the Secondary Development Model of Traditional Chinese Medicine
1. College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China
2. Inner Mongolia Enterprise Key Laboratory of Innovative Mongolian Medicine Research, Inner Mongolia Grand Pharmaceutical Co., Ltd, Hohhot 010110, China
| Abstract: | Ethnic medicine is an important part of the Chinese medicine system in China. The secondary development mode of traditional Chinese medicine has promoted the technological upgrading of the pharmaceutical industry, while pointing out the direction for the modernization and industrialization of ethnic medicine. This paper briefly analyzes the current situation of Mongolian medicine industry and points out that cultivating Mongolian medicine variety needs to establish the re-development mode based on the secondary development strategy of traditional Chinese medicine and carrying out the re-invention of Mongolian medicine. Taking Mongolian medicine seabuckthorn syrup as an example, this paper systematically elaborates modern research on Mongolian medicine in five major aspects: Quality standard establishment, Process optimization, Active ingredient analysis, Pharmacological and toxicological research, and Clinical re-evaluation, and establishes the secondary development model of Mongolian medicine from an empirical perspective. Through the secondary development strategy, it can not only establish the theoretical system from pharmacological research to clinical evaluation and form systematic research results, but also precisely locate the clinical indications of Mongolian medicines, guide clinical use, monitor adverse reactions, and finally ensure the safe and effective clinical use of medicines. The "superiority and inferiority" effect formed by the secondary development of Mongolian medicines can expand the market share of medicines, promote the emergence of large varieties of Mongolian medicines, and push forward the prosperity and development of Mongolian medicine industry. |
| Keywords: | Secondary Development; Mongolian Medicine; Sea-buckthorn |
| DOI: | 10.57237/j.cmrd.2023.01.005 |
View:
Downloads:
Received: 3 February 2023
Accepted: 15 March 2023
Published Online: 28 March 2023
Funding
| 1. | 内蒙古自治区关键技术攻关计划项目《“药食同源”蒙药材沙棘有效提取物的新工艺研究和药效学研究》(项目编号: 2021GG0185) |
| 2. | 呼和浩特市应用技术研究与开发资金项目《蒙药沙棘二次开发-沙棘糖浆有效成分分类解析及物质基础研究》(项目编号: 2021—合—1) |
References
| [1] | 张伯礼, 程翼宇, 瞿海斌, 等. 中成药二次开发核心技术体系创研及其产业化 [J]. 天津中医药, 2015, 32 (01): 1-3. |
| [2] | 肖云峰, 常福厚, 钱新宇, 等. 蒙药的现状与发展 [C]. 中国毒理学会中药与天然药物毒理与安全性评价第四次（2019年）学术年会论文集. 中国毒理学会会议论文集, 2019: 93-98. |
| [3] | 张小敏, 佟海英, 那生桑, 等. 蒙药经典制剂的蒙医与西医双向临床定位方法 [J]. 中医药导报, 2022, 28 (08): 41-4. |
| [4] | 梁国栋, 赵粉荣. 蒙药沙棘概况及其现代研究开发现状 [J]. 中国民族医药杂志, 2019, 25 (02): 41-4. |
| [5] | 黄卫华, 黄国兴. 芦麦合剂联合沙棘糖浆治疗小儿厌食症的效果分析 [J]. 健康大视野, 2019, (22): 102-3. |
| [6] | 林海, 梁国栋. 沙棘糖浆联合枸橼酸莫沙必利片治疗儿童功能性消化不良的临床研究 [J]. 内蒙古医科大学学报, 2020, 42 (06): 645-7+65. |
| [7] | 姜桂霞. 雾化吸入盐酸氨溴索治疗小儿支气管炎的临床疗效观察 [J]. 大家健康 (学术版), 2015, 9 (01): 99-100. |
| [8] | 左阳, 陈娟. 沙棘糖浆、氨溴特罗口服液联合治疗小儿支气管炎的体会 [J]. 世界最新医学信息文摘, 2019, 19 (92): 232. |
| [9] | 朱丹荣, 钱娟, 董娜, 等. 沙棘糖浆联合布地奈德雾化吸入治疗小儿毛细支气管炎的临床研究 [J]. 内蒙古医科大学学报, 2020, 42 (02): 153-5. |
| [10] | 郭亚健, 范莉, 王晓强, 等. 关于NaNO2-Al (NO3)3-NaOH比色法测定总黄酮方法的探讨 [J]. 药物分析杂志, 2002, 02): 97-9. |
| [11] | 何珺, 颜仁梁, 刘志刚. NaNO2-Al (NO3)3-NaOH比色法测定总黄酮应用中的常见问题 [J]. 今日药学, 2009, 19 (12): 18-21. |
| [12] | 田志杰, 李彭帅, 于海泉. 药用沙棘果汁生产方法, CN111671783A [P/OL]. 2020-09-18]. |
| [13] | 王宁宁, 郑文惠, 张凯雪, 等. 沙棘的化学成分、药理作用研究进展及其质量标志物的预测分析 [J]. 中国中药杂志, 2021, 46 (21): 5522-32. |
| [14] | 娜黑芽, 张晓玲, 陈怡璇, 等. 药用沙棘果汁中1个新的黄酮苷类化合物 [J]. 中草药, 2022, 53 (03): 659-66. |
| [15] | 梁国栋, 吴启进, 娜黑芽. 沙棘糖浆止咳祛痰作用的实验研究 [J]. 药学研究, 2020, 39 (10): 562-4+74. |
| [16] | XIAO-LING Z, HEI-YA N, PENG-SHUAI L, et all. Hipponorterpenes A and B, two new 14-noreudesmane-type sesquiterpenoids from the juice of Hippophae rhamnoides [J]. Phytochemistry Letters, 2022, 52. |
| [17] | DóRA R, NORBERT K, TíMEA R, et al. 14-Noreudesmanes and a phenylpropane heterodimer from sea buckthorn berry inhibit Herpes simplex type 2 virus replication [J]. Tetrahedron, 2018, 75 (10). |
| [18] | REN R, LI N, SU C, et al. The bioactive components as well as the nutritional and health effects of sea buckthorn [J]. RSC Adv, 2020, 10 (73): 44654-71. |
| [19] | 南星梅, 顾健. 藏药五味沙棘口服液对实验性慢性支气管炎大鼠模型的防治作用研究 [J]. 西南民族大学学报 (自然科学版), 2015, 41 (03): 299-304. |
| [20] | 梁国栋, 吴启进, 娜黑芽. 沙棘糖浆对食积症模型小鼠的消食化滞作用 [J]. 药学研究, 2020, 39 (09): 501-3+39. |
| [21] | 高琴琴, 梁国栋, 周泽璇, 等. 蒙药沙棘糖浆对14日龄SD大鼠的急毒与长毒试验研究 [J]. 中国药物警戒, 1-8. |
| [22] | 史伟新. 沙棘糖浆治疗小儿呼吸道感染的作用浅析 [J]. 世界最新医学信息文摘, 2019, 19 (92): 229. |
| [23] | CHEN X, SHU J H, HUANG Y, et al. Therapeutic effect of budesonide, montelukast and azithromycin on post-infectious bronchiolitis obliterans in children [J]. Exp Ther Med, 2020, 20 (3): 2649-56. |
| [24] | 黄妙毅, 杜旭升. 布地奈德对哮喘大鼠气道重塑及气道平滑肌中Toll样受体4表达的影响 [J]. 陕西医学杂志, 2015, 44 (05): 524-6. |
| [25] | 薛武更, 段锦绣, 张伟娜, 等. 中成药不合理使用的常见原因及对策 [J]. 中国中医药现代远程教育, 2023, 21 (01): 169-71. |
| [26] | 田颖, 郭栋, 彭伟, 等. 基于循证的中成药治疗原发性高血压临床证据评价 [J]. 中华高血压杂志, 2022, 30 (10): 956-63. |
| [27] | 司富春, 高燕. 加快推进中医药国际化发展研究 [J]. 中医研究, 2021, 34 (7): 1-4. |
| [28] | 孙昱, 徐敢, 汪祺. 中药二次开发的研究思路探讨 [J]. 中草药, 2021, 52 (13): 4107-13. |
| [29] | 查娜, 布音, 萨础拉. 蒙药质量标准化研究发展概况 [J]. 亚太传统医药, 2022, 18 (11): 6-10. |
| [30] | 戴胜云, 刘杰, 乔菲, 等. 基于1994—2021年专利分析民族药的发展及思考 [J]. 药物分析杂志, 2022, 42 (08): 1290-305. |
| [31] | 左相龙. 内蒙古自治区发展蒙中药产业的思考 [J]. 中国经贸导刊 (中), 2019, 03): 40-1. |
| [32] | 王永炎. 聚焦关键环节 创新发展新时代中药产业 [J]. 中国科技产业, 2022, (09): 8-9. |
Join the Editorial Board
We invite active, qualified and high profile scientists and researchers to join as Editorial Board Members.
Join UsBecome a Reviewer
Scholars with a strong interest in reviewing are invited to join the reviewer panel to ensure the quality of the research to be published.
Join Us